Avantor Inc.

AVTR | NYSE

Price Alert Chart Builder DCF Calculator

$15.52

-$0.34 (-2.14%)

At close: Sep 18, 2026, 4:00 PM ET

$15.51

-$0.01 (-0.06%)

After-hours: Sep 18, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.14%

(1D)

Rating

Updated: Aug 26, 2026

23.8

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $10.5B

1D Range

15.44 15.90

52W Range

7.27 16.05

Valuation (TTM)

PE -18.48

PB 1.86

EV/EBITDA 519.15

Valuation (NTM)

Forward PE 17.53

Forward PEG -2.12

Price Target $11.67

Cash Flow

FCF Yield 2.8%

SBC Adj. FCF Yield 2.4%

SBC Impact -13.3%

Margins

Gross Margin 31.8%

Operating Margin -4.3%

FCF Margin 4.4%

Growth (CAGR)

Revenue 3Y | 5Y -2.9% | -1.4%

Dil EPS 3Y | 5Y -295.7% | -70.1%

FCF 3Y | 5Y -26.3% | -20.4%

Returns

ROA -5.0%

ROE -10.3%

ROIC -2.8%

Financial Health

Net Cash

$269.8M

Current Ratio 1.78

Interest Coverage -1.60

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 13,500

IPO Date May 16, 2019

Website www.avantorsciences.com

Fiscal Year January - December

Full Company Profile

Latest News

6 hours ago · prnewswire.com

Avantor appoints new Chief Financial Officer

RADNOR, Pa., Sept. 21, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, appoints Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026.

3 days ago · zacks.com

Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC

AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.

4 days ago · zacks.com

Here's Why You Should Add Avantor Stock to Your Portfolio for Now

AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.

17 days ago · zacks.com

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

24 days ago · zacks.com

Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?

Avantor (AVTR) reported earnings 30 days ago. What's next for the stock?

27 days ago · zacks.com

Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?

AVTR's Revival Program is lifting VWR growth and BMP orders, but margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook.

1 month ago · zacks.com

Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

2 months ago · zacks.com

Are Medical Stocks Lagging Avantor (AVTR) This Year?

Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.

2 months ago · zacks.com

Avantor, Inc. (AVTR) Just Flashed Golden Cross Signal: Do You Buy?

Avantor, Inc. (AVTR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AVTR's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.